These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The effect of mammographic screening and hormone replacement therapy use on breast cancer incidence in England and Wales.
    Author: Waller M, Moss S, Watson J, Møller H.
    Journal: Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2257-61. PubMed ID: 18006913.
    Abstract:
    DESIGN: An extended age-period-cohort model was used to estimate the effect of mammographic screening and hormone replacement therapy on breast cancer incidence in England and Wales between 1971 and 2001. RESULTS: Incidence of breast cancer increased noticeably in women attending screening for the first time compared with nonattenders [rate ratio (RR), 1.73; 95% confidence interval (95% CI), 1.67-1.80]. Incidence was also 18% to 35% higher in attenders relative to nonattenders in subsequent screening rounds. In the first 3 years after women left the screening program, rates of breast cancer were reduced (RR, 0.88; 95% CI, 0.86-0.90), but by 7 to 9 years after screening, the rates had returned to the expected level (RR, 0.97; 95% CI, 0.94-1.00). The estimated RR of hormone replacement therapy on breast cancer incidence was 1.55 (95% CI, 1.37-1.75). Screening is estimated to increase a woman's lifetime risk of being diagnosed with breast cancer from 7.8% to 8.6%. CONCLUSIONS: It is estimated that in the absence of screening, rates of breast cancer incidence would have continued to increase. A study at the individual subject level would be beneficial to assess the level of overdiagnosis associated with breast cancer screening.
    [Abstract] [Full Text] [Related] [New Search]